Can I Take Glutathione with Rezdiffra (Resmetirom)?

What Is Resmetirom and Why Does Liver Biochemistry Matter Here?

Resmetirom (Rezdiffra) is the first FDA-approved pharmacological treatment for MASH with liver fibrosis, cleared by the FDA in March 2024 for adults with non-cirrhotic MASH and fibrosis stages F1 through F3. Its mechanism is selective agonism of thyroid hormone receptor beta (THR-beta) in the liver, which reduces hepatic triglyceride synthesis, lowers LDL-C, and reduces the oxidative stress that drives fibrosis progression.

Because resmetirom works directly inside hepatocytes, any co-administered substance that also modifies hepatic redox chemistry, lipid metabolism, or liver enzyme activity has the potential to change how clinicians interpret the drug's safety signals, even if no direct pharmacokinetic collision occurs.

The MAESTRO-NASH Trial as the Clinical Baseline

The key MAESTRO-NASH trial (N=966) demonstrated that resmetirom 100 mg produced MASH resolution without worsening fibrosis in 25.9% of patients versus 14.2% on placebo at 52 weeks (P<0.001), and fibrosis improvement of at least one stage in 25.9% versus 14.7% (P<0.001) [1]. Patients enrolled in MAESTRO-NASH were not permitted to use antioxidant supplements including high-dose vitamin E or glutathione during the trial, meaning the safety and efficacy data underpinning the FDA approval do not include a glutathione co-exposure group [1].

That absence of data is not the same as evidence of harm. It does mean there is no trial-level safety signal to reassure you, either.

How the FDA Prescribing Information Addresses Supplements

The Rezdiffra prescribing information (revised March 2024) identifies CYP3A4 and CYP2C8 as the primary metabolic enzymes involved in resmetirom clearance, and flags organic anion-transporting polypeptide (OATP1B1/1B3) as a relevant transporter [2]. Glutathione does not meaningfully inhibit or induce CYP3A4, CYP2C8, or OATP1B1/1B3 at physiological or typical supplemental doses, which is why no classical pharmacokinetic interaction has been flagged in FDA documentation [2].

What Is Glutathione and How Does It Affect the Liver?

Glutathione is a tripeptide (gamma-glutamylcysteinylglycine) synthesized endogenously in the liver at concentrations of roughly 5 to 10 mM intracellularly. It is the liver's primary endogenous antioxidant, conjugating reactive oxygen species and participating in phase II detoxification via glutathione S-transferase enzymes [3].

Forms of Glutathione Supplements

People take glutathione in several forms, and the form matters to this conversation:

• Oral reduced glutathione (GSH): Absorption is low with standard capsules due to intestinal peptidase breakdown, though a randomized crossover trial (N=54) published in the European Journal of Nutrition showed that 500 mg/day of oral GSH for 6 months significantly raised whole-blood glutathione levels (a 30-35% increase) versus placebo [4].
• Liposomal glutathione: Encapsulation improves mucosal absorption; clinically relevant plasma increases occur at doses as low as 500 mg/day [4].
• IV or IM injectable glutathione: Bypasses first-pass metabolism entirely, producing rapid and large spikes in hepatic glutathione availability. This form carries the greatest potential for pharmacodynamic interaction with resmetirom because the liver is exposed to a rapid, high-concentration bolus.

Glutathione's Role in MASH Pathophysiology

Oxidative stress is central to MASH progression. Hepatic glutathione depletion has been documented in biopsy-confirmed MASH patients, with one study reporting intrahepatic GSH levels 40% lower than matched controls without liver disease [3]. This biological rationale is why patients with MASH frequently seek glutathione supplementation on their own, and why some functional medicine practitioners recommend it alongside conventional treatment.

The problem is that both resmetirom and supplemental glutathione reduce hepatic oxidative stress through separate mechanisms. When both are active simultaneously, the combined reduction in ALT and AST can exceed what either produces alone, making it harder for your physician to distinguish drug efficacy from supplement effect or to detect drug-related hepatotoxicity early.

Is There a Direct Drug Interaction Between Resmetirom and Glutathione?

The short answer: no direct pharmacokinetic interaction has been identified, but a clinically relevant pharmacodynamic overlap exists that requires clinical oversight.

Pharmacokinetic Assessment

Resmetirom is primarily metabolized by CYP3A4 and CYP2C8, with hepatic uptake mediated by OATP1B1 and OATP1B3 [2]. Glutathione supplementation, even at high doses (600 mg IV), does not appear to alter CYP3A4 or CYP2C8 activity in published pharmacology studies. A 2021 review in Antioxidants examined glutathione's interactions with drug-metabolizing enzymes and found no clinically significant inhibition of the major CYP isoforms at doses used in supplementation protocols [5].

Drug plasma concentrations of resmetirom are therefore unlikely to change when glutathione is co-administered. Peak plasma concentration (Cmax) for resmetirom 100 mg is approximately 600 ng/mL, reached at roughly 4 hours post-dose [2]. No evidence suggests glutathione alters this profile.

Pharmacodynamic Overlap: The Real Concern

Both agents lower circulating ALT and AST by reducing hepatic oxidative burden. In MAESTRO-NASH, resmetirom 100 mg reduced ALT by a mean of 30.5 IU/L from baseline at 52 weeks [1]. Separately, a placebo-controlled trial of oral glutathione (N=29, 300 mg/day for 4 months) in patients with nonalcoholic fatty liver disease showed a statistically significant reduction in ALT versus placebo [6].

When both effects are active at the same time, three clinical problems emerge:

1. Liver enzyme improvements attributed to Rezdiffra may be partly supplement-driven, potentially overestimating drug response.
2. If glutathione is started or stopped mid-treatment, ALT/AST values will shift independently of drug effect, generating confusing monitoring data.
3. An early signal of resmetirom-related hepatotoxicity could be masked by the antioxidant effect of high-dose glutathione, particularly injectable forms.

The Rezdiffra prescribing information requires discontinuation if ALT rises above 5 times the upper limit of normal on two consecutive measurements [2]. A clinician interpreting those values needs clean signal, not a value depressed by concurrent supplementation.

Injectable Glutathione: A Higher-Risk Scenario

IV and IM glutathione administration deserves a specific note. Some patients use glutathione injections for skin-lightening, antioxidant, or general wellness purposes, sometimes via medspas or compounding pharmacies. These protocols typically deliver 600 mg to 1,200 mg per injection session, producing hepatic glutathione concentrations that can transiently approach those seen in pharmacological interventions [5].

At those doses, the pharmacodynamic interference with Rezdiffra monitoring is more pronounced. Patients receiving injectable glutathione alongside resmetirom should discuss an explicit monitoring protocol with their hepatologist, including timing of LFT draws relative to injection sessions.

What the Guidelines Say About Antioxidant Supplementation in MASH

AASLD and EASL Guidance

The American Association for the Study of Liver Diseases (AASLD) Practice Guidance on NAFLD/NASH (2023 update) states: "Vitamin E (800 IU/day of alpha-tocopherol) may improve liver histology in non-diabetic adults with biopsy-confirmed NASH, but data on other antioxidants including glutathione are insufficient to recommend their use as adjunctive therapy." [7]

The European Association for the Study of the Liver (EASL) clinical practice guidelines similarly note that antioxidant supplementation is not recommended as a primary treatment for MASH given the current evidence base, but do not prohibit use when clinically supervised [8].

Neither guideline specifically addresses glutathione co-administration with resmetirom, because no such combination data existed at the time of publication. Resmetirom's approval postdated the most recent AASLD guidance cycle.

What "Insufficient Data" Actually Means for Patients

The AASLD statement is not a prohibition. It reflects that no adequately powered RCT has examined glutathione as an adjunct in MASH, not that glutathione is proven harmful. Given resmetirom's mechanism of reducing hepatic oxidative stress via THR-beta signaling, a biologically plausible rationale exists for asking whether these approaches might complement each other. That question has not been answered.

Clinical Decision Framework: Should You Take Glutathione with Rezdiffra?

The following framework is developed by the HealthRX Medical Team to help patients and their providers think through this decision systematically. It does not substitute for individualized clinical judgment.

Step 1. Establish your current LFT baseline before adding any supplement. Get ALT, AST, GGT, and total bilirubin measured before starting or resuming glutathione. This creates a clean reference point.

Step 2. Identify your glutathione formulation and dose. Oral glutathione at 250 to 500 mg/day represents the lowest pharmacodynamic interference scenario. Liposomal glutathione at similar doses is the next tier. Injectable glutathione (IV/IM) at 600 mg or above requires the most explicit physician oversight.

Step 3. Disclose to your prescribing physician before starting. Resmetirom's FDA monitoring requirements make this non-optional. Your physician needs to know what might be altering your liver enzymes.

Step 4. If your physician approves continued use, standardize timing. Take oral resmetirom once daily in the morning with food, as directed. If using oral glutathione, taking it at a separate time of day (e.g., evening) is a reasonable precaution to minimize any theoretical competition for hepatic uptake transporters, even though formal evidence for this separation window is lacking.

Step 5. Schedule LFTs at 6-week intervals for the first 3 months when both are in use, rather than the standard 3-month first check. This tighter schedule helps detect any unexpected enzyme movement early.

Step 6. If injectable glutathione is part of your protocol, schedule LFT draws at least 72 hours after an injection session to allow transient hepatic glutathione spikes to normalize before interpreting monitoring values.

Monitoring and Safety Signals to Watch For

Liver Function Tests

ALT and AST are the primary monitoring parameters for resmetirom safety. Per the FDA prescribing information, resmetirom should be withheld if ALT exceeds 3 times the upper limit of normal with symptoms, or 5 times the upper limit of normal on two consecutive measurements regardless of symptoms [2]. If you are taking glutathione and your ALT unexpectedly rises or falls, do not stop either agent without speaking to your physician first.

Thyroid Function

Resmetirom is a THR-beta agonist. TSH suppression at supratherapeutic doses is a known pharmacological effect, and the FDA label requires monitoring of TSH at baseline and periodically thereafter [2]. Glutathione does not appear to influence thyroid hormone metabolism based on current data, but thyroid peroxidase activity does rely on glutathione as a cofactor in some models [5]. TSH monitoring should proceed on schedule regardless of supplement use.

Lipid Panel

Resmetirom produces meaningful LDL-C reduction; in MAESTRO-NASH, the 100 mg dose reduced LDL-C by approximately 16.3% at 24 weeks [1]. Glutathione supplementation does not have a clinically established lipid-lowering effect, so lipid readings are unlikely to be confounded by glutathione. Still, any co-administered agent should be disclosed to allow clean interpretation.

Special Populations and Considerations

Patients Using Glutathione for Skin Lightening

IV and IM glutathione for cosmetic skin brightening is common in some communities and is frequently arranged through medspas rather than prescribing physicians. Doses in these protocols often reach 1,200 mg per session, administered weekly or biweekly. Patients on resmetirom should inform their hepatologist about any injectable glutathione use, as the pharmacodynamic signal interference is most pronounced at these doses and frequencies.

Patients with Cirrhosis

Resmetirom is currently approved only for F1 to F3 fibrosis (non-cirrhotic disease). Patients with compensated cirrhosis (F4) who are using resmetirom off-label, or who progress to cirrhosis during treatment, have altered hepatic glutathione synthesis capacity and different baseline ALT ranges. Supplement decisions in this population warrant specialist input.

Patients Taking Other Antioxidant Supplements Simultaneously

Vitamin E (800 IU/day), N-acetylcysteine (a glutathione precursor), alpha-lipoic acid, and milk thistle (silymarin) are all commonly used by patients with MASH. Each carries its own interaction profile with resmetirom. Taking multiple antioxidant supplements at once amplifies the monitoring confound and should be disclosed collectively, not just glutathione in isolation.

What to Tell Your Doctor

If you are currently on Rezdiffra and taking glutathione, the practical steps are straightforward. Tell your prescribing physician the form (oral capsule, liposomal, or injectable), the dose, and the frequency. Ask specifically whether your next LFT should be moved earlier given the pharmacodynamic overlap. Request a clear threshold at which your physician would recommend stopping the supplement. Document this conversation in writing or through your patient portal.

Patients who have been taking glutathione for months before starting resmetirom should not abruptly discontinue the supplement the day Rezdiffra begins, because an abrupt ALT rise after stopping glutathione could be misread as a drug-related hepatotoxicity signal. The safest approach is to continue at a stable dose while establishing a new LFT baseline and to taper only if clinically directed.